What Trilogy Writing & Consulting does

Trilogy Writing & Consulting GmbH is a Frankfurt, Germany-based professional services firm founded in 2002 that provides specialized regulatory and clinical documentation services to life sciences and pharmaceutical companies. Its work centers on producing the documentation required across the clinical development lifecycle — including clinical study reports, regulatory dossiers, and submissions to agencies such as the FDA and EMA — for therapies including biologics and specialty drugs. The firm addresses documented customer pain points around regulatory complexity, rising clinical trial volume, and the need for compliant technical writing under stringent frameworks.

Trilogy operates as a B2B professional services provider rather than a software platform; value is delivered through human regulatory writing expertise, and the underlying "technology" in the disclosed data is not characterized beyond standard professional services tooling. The company serves a single primary vertical (pharmaceutical and life sciences sponsors) and, based on available commentary, reaches customers via direct and enterprise sales channels. Pricing models, contract structures, revenue mechanics, and named customers are not publicly disclosed, and no app, API, or productized technology offering is described in the source material.

In March 2024, Trilogy was acquired by Indegene Limited, a strategic operating company in the broader pharma services space. The acquisition folded Trilogy into Indegene's medical writing and regulatory services portfolio, giving it access to a larger ecosystem of digital, medical, and commercial capabilities and a wider geographic footprint than Trilogy likely operated as an independent firm. Operating geographies, named customers, leadership team, and financial performance are not disclosed in the available sources, limiting visibility into post-acquisition scale and trajectory.

Name

Trilogy Writing & Consulting

Legal name

Trilogy Writing & Consulting GmbH

Website

https://trilogywriting.com

Company type

Private

Founded year

2002

Operating status

Acquired

Headcount range

101–250 employees

Short description

Trilogy Writing & Consulting is a Frankfurt-based regulatory writing consultancy serving pharmaceutical and life sciences companies with clinical and regulatory documentation. Founded in 2002, the firm has been a subsidiary of Indegene Limited since March 2024.

Ownership category

akta.pro rank

Headquarters

HQ city

Frankfurt

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Core offering

Trilogy Writing & Consulting provides specialized regulatory and clinical documentation services for the life sciences sector. The firm supports pharmaceutical and biotechnology companies in producing documentation required for clinical development, regulatory submissions, and compliance with stringent regulatory frameworks. It operates as a regulatory medical writing consultancy with deep domain expertise in clinical and submission documentation.

Differentiator

Problem solved

Functional benefit

Products and services

• Regulatory Medical Writing Services
• Clinical Trial Documentation Support
• Regulatory Compliance Documentation for Biologics and Specialty Drugs

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves1 record

Expansion highlights4 records

Broad incumbents

• Labcorp Drug Development (Covance): Labcorp Drug Development, formerly Covance, provides clinical development and regulatory services including medical writing to pharma sponsors. Its integrated CRO model with embedded writing functions makes it a broadly comparable incumbent peer to Trilogy's specialized offering.
• ICON plc: ICON is a leading global CRO with significant regulatory writing, biostatistics, and clinical services capabilities. It is a direct competitor for outsourced regulatory writing contracts with pharma and biotech sponsors and offers comparable FSP-style engagements at global scale.
• Indegene Limited: Indegene is Trilogy's parent company and a global healthcare commercialization and clinical services firm. While Indegene operates across the broader pharma services value chain, its regulatory writing portfolio — of which Trilogy is the centerpiece — directly overlaps with Trilogy's specialty. It is the most relevant comparison for benchmarking Trilogy's service scope and scale within a strategic acquirer's platform.
• IQVIA: IQVIA is a global CRO and life sciences services giant offering regulatory and medical writing within its broader clinical development portfolio. While its remit extends across the full clinical and commercial stack, its medical writing practice competes for the same embedded writing engagements Trilogy targets, making it a relevant broad incumbent peer.
• Syneos Health: Syneos Health is a clinical and commercial services organization offering regulatory and medical writing within its broader biopharmaceutical solutions portfolio. It serves similar sponsor customers and competes for similar writing engagements.

Direct peers

• Parexel International: Parexel is a top-tier CRO with dedicated regulatory writing and medical communications services serving global pharma and biotech sponsors. It competes directly with Trilogy for the same regulatory documentation work and across similar clinical submission use cases, and is one of the most direct comparables in the medical writing FSP space.
• Freyr Solutions: Freyr is a global regulatory services and medical writing specialist serving pharma, biotech, and medical device companies. Its dedicated focus on regulatory documentation, submissions, and compliance aligns closely with Trilogy's core offering and customer base.
• Cactus Communications: Cactus Communications, through its Cactus Life Sciences division, provides medical writing, publication support, and regulatory documentation services to global pharma and biotech sponsors. It is one of the closest direct peers to Trilogy in terms of pure-play medical writing and FSP offerings for clinical and regulatory documents.

Emerging players

• ProPharma Group (now part of PACE): ProPharma Group provides regulatory affairs, compliance, and medical writing consulting services to pharma and biotech. Its overlap with Trilogy is more concentrated in regulatory and quality-focused projects, positioning it as a focused emerging player in adjacent regulatory services.

Regional players

• TFS HealthScience / Ergomed: TFS HealthScience (acquired by Ergomed) is a European-headquartered CRO with a strong medical writing and clinical services practice serving global sponsors. Its Nordic and European base, combined with writing-focused FSP services, makes it a directly comparable European regional peer to Trilogy's Frankfurt-rooted operation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/trilogywriting
• Facebookfacebook.com/TrilogyWriting
• LinkedInlinkedin.com/company/trilogy-writing-and-consulting

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trilogy Writing & Consulting